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Abstract
Background: Vpx is a non-structural protein coded by members of the SIVSM/HIV-2 lineage that
is believed to have originated by duplication of the common vpr gene present in primate
lentiviruses. Vpx is incorporated into virion particles and is thus present during the early steps of
viral infection, where it is thought to drive nuclear import of viral nucleoprotein complexes. We
have previously shown that Vpx is required for SIVMAC-derived lentiviral vectors (LVs) infection of
human monocyte-derived dendritic cells (DCs). However, since the requirement for Vpx is specific
for DCs and not for other non-dividing cell types, this suggests that Vpx may play a role other than
nuclear import.
Results: Here, we show that the function of Vpx in the infection of DCs is conserved exclusively
within the SIVSM/HIV-2 lineage. At a molecular level, Vpx acts by promoting the accumulation of full
length viral DNA. Furthermore, when supplied in target cells prior to infection, Vpx exerts a similar
effect following infection of DCs with retroviruses as divergent as primate and feline lentiviruses
and gammaretroviruses. Lastly, the effect of Vpx overlaps with that of the proteasome inhibitor
MG132 in DCs.
Conclusion: Overall, our results support the notion that Vpx modifies the intracellular milieu of
target DCs to facilitate lentiviral infection. The data suggest that this is achieved by promoting viral
escape from a proteasome-dependent pathway especially detrimental to viral infection in DCs.
Background
Vpx is a non-structural protein coded by members of the
SIVSM/HIV-2 lineage, but absent in HIV-1 and in most SIV
lineages [1]. Vpx is important for viral replication in
macaques [2], but its functions during the early steps of
the viral life cycle remain controversial. A number of stud-
ies correlated the loss of nuclear localization of Vpx with
the inability of mutant viruses to infect non-dividing cells,
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thus arguing for its role in nuclear import, similarly to
HIV-1 Vpr [3-12]. However, several studies indicated that
Vpx localization was more complex and that Vpx-deficient
mutants were defective independently of the cells' cycling
status, suggesting a function other than nuclear import
[13-19]. It is highly possible that these discrepancies result
from the heterogeneity of the experimental systems used.
None of the previous studies examined the function of
Vpx in the infection of DCs.
We have previously shown that in a single round infectiv-
ity assay, Vpx is absolutely required for the infection of
human monocyte-derived DCs by SIVMAC LVs, while it is
largely dispensable for the infection of other non-dividing
cell types [20,21]. Interestingly, we have also shown that
Vpx can be functionally provided in trans by pre-incuba-
tion of DCs with non-infectious SIVMAC VLPs. In this set-
ting, VLPs composed of viral structural and accessory
proteins but devoid of viral genome are simply used as
carriers of those viral proteins that are normally delivered
in target cells upon viral infection. By analyzing VLPs of
different composition, we have determined that Vpx is the
sole viral protein required for the positive effect of SIVMAC
VLPs (named hereafter Vpx-VLPs, [20]). Upon pre-incuba-
tion, Vpx increased the infectivity of the closely related
HIV-1 lentiviral vector by at least 10-fold [20]. This effect
was specific for DCs and to a milder extent for macro-
phages and occurred in the absence of detectable changes
in DCs physiology.
Here, we investigated Vpx functions at a molecular level
and showed that Vpx proteins derived from different
strains of the SIVSM/HIV-2 lineage act by promoting the
rapid accumulation of full length viral DNA following
infection with a wide variety of retroviruses. More impor-
tantly, we discovered that MG132, a known proteasome
inhibitor, partially rescues the defect of Vpx-deficient SIV-
MAC LVs and displays effects similar and non-additive to
Vpx in the infection of DCs by HIV-1.
Results
The positive effect of Vpx in lentiviral infection of human 
DCs is a unique property of members of the SIVSM/HIV-2 
lineage
To determine if the requirement for Vpx in the infection
of DCs was conserved in other members of the SIVSM/HIV-
2 lineage, DCs were infected with SIVMAC and HIV-2 LVs
coding or lacking Vpx. Cells were analyzed 3 days later by
flow cytometry to score GFP positive infected cells (Fig.
1A). HIV-2 LVs were capable of infecting DCs but relied
on the presence of Vpx, as we previously reported for SIV-
MAC LVs [20].
Given that Vpx rescues the infectivity defect of Vpx-defi-
cient SIVMAC LVs when supplied in target cells via non-
infectious Vpx-VLPs, we sought to determine if pre-incu-
bation could similarly rescue Vpx-deficient HIV-2 LVs
(Fig. 1A). Pre-incubation of DCs with Vpx-VLPs had only
marginal effects on the efficiency of infection of complete
(Vpx-containing) HIV-2 and SIVMACLVs (1.5–2 fold posi-
tive and a 1.5–2 fold decrease, respectively). On the con-
trary, pre-incubation completely rescued the defect of
Vpx-deficient HIV-2 LVs, demonstrating that HIV-2 and
SIVMAC Vpx proteins have conserved functions.
To extend our observation further, the Vpx proteins of SIV-
MAC and HIV-2 were compared with the one derived from
the red capped mangabey SIV (SIVRCM) with which they
share only 30% sequence identity. Proteins were flag-
tagged at their N-terminus, as no available antibody
allowed SIVRCM Vpx detection. The ability of these pro-
teins to functionally replace SIVMAC Vpx was first assayed
in the context of SIVMAC LVs infection (Fig. 1B). Vpx pro-
teins were co-expressed along with minimal SIVMAC LVs
(SIV15-, coding only gag-pro-pol) and virion particles were
purified and normalized. DCs were then infected at high
and low viral inputs (Fig. 1B, MOIs 0.3 and 3, as assessed
on HeLa cells). Despite being well incorporated into vir-
ion particles (right panel, as indicated), SIVRCM Vpx was
unable to functionally complement the infectivity defect
of Vpx-deficient SIVMAC LVs. Similarly, SIVRCM Vpx-con-
taining VLPs had no positive effect on the infectivity of
WT HIV-1 LVs in a typical pre-incubation assay (Fig. 1C).
As we had previously shown, similar effects were observed
with WT or Vpr-deficient HIV-1 vectors, suggesting that
Vpr didn't share similar functions than Vpx (not shown
and [20]).
Given that Vpx proteins derived from other strains of the
SIVSM/HIV-2 lineage tested behaved as shown for HIV-2
and SIVMAC (not shown), these results suggest that the
function of Vpx in the infection of DCs is unique to mem-
bers of this lineage.
Vpx allows the accumulation of full length viral DNA 
following SIVMAC LVs infection of DCs
To dissect the effects of Vpx at a molecular level, the accu-
mulation of reverse transcription intermediates was ana-
lyzed by semi-quantitative PCR on DCs lysates obtained
upon infection with SIVMAC LVs containing or not Vpx
(Fig. 2). PCR products were transferred onto a nylon
membrane, hybridized with 32P-labelled specific probes
and analyzed by phosphor imager quantification.
Early RT products (minus strand strong stop, MSSS) were
readily detected, although a minor defect in MSSS accu-
mulation was observed at 24 hrs post infection in the
absence of Vpx (2.5 fold after mtDNA normalization). In
contrast, accumulation of full length (FL) viral DNAs was
drastically reduced in the absence of Vpx (at least 100Retrovirology 2007, 4:2 http://www.retrovirology.com/content/4/1/2
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fold). Not surprisingly, no episomal 2LTRs forms were
detected in this case.
These results strongly suggest that Vpx is required in DCs
for the accumulation of full length viral DNA during the
early steps of SIVMAC infection.
Vpx has a wide positive effect on viral infection of DCs and 
acts by promoting the accumulation of full length viral 
DNA
To explain the positive effect of Vpx on the efficiency of
infection of an heterologous virus (HIV-1, [20]), two
hypotheses were put forward: Vpx could bind to a con-
The function of Vpx in the infection of DCs is conserved uniquely in members of the SIVSM/HIV-2 lineage Figure 1
The function of Vpx in the infection of DCs is conserved uniquely in members of the SIVSM/HIV-2 lineage. A) 
HIV-2 and SIVMAC LVs rely on Vpx for the infection of DCs. VSVg-pseudotyped SIVMAC and HIV-2 LVs (coding or not for Vpx) 
were produced in 293T cells, purified by ultracentrifugation and used to infect DCs at a multiplicity of infection (MOI) of 3. 
Vpx-containing SIVMAC VLPs (Vpx-VLPs) similarly produced were added onto DCs at MOI equivalent of 2 (as measured by exo-
RT test with standards of known infectivity) for 2 hrs prior to infection with the above-mentioned LVs. GFP+ cells were scored 
3 days later by flow cytometry. B) Only Vpx proteins from the SIVSM/HIV-2 lineage rescue the infectivity defect of Vpx-deficient 
SIVMAC LVs. VSVg-pseudotyped SIVMAC LVs (SIV15-, coding gag-pro-pol) were produced in presence or absence of Flag-tagged 
Vpx proteins derived from SIVMAC, SIVRCM and HIV-2. Virions were then normalized for their infectious titer on HeLa cells and 
used to infect DCs at MOI 0.3 or 3. The incorporation of Flag-Vpx proteins into virion particles was assessed by Western blot 
(right panel). The different migration on SDS-PAGE of HIV-2 and SIVMAC Vpx proteins has already been reported [40]. C) Only 
Vpx proteins from the SIVSM/HIV-2 lineage increase WT HIV-1 LVs infection in a pre-incubation assay. Non-infectious SIVMAC 
VLPs containing the different Flag-Vpx proteins were produced and used as described in A in a pre-incubation assay to test 
their effect on WT HIV-1 LVs infectivity (used at a constant MOI of 3). Incorporation of Flag-Vpx proteins into VLPs was 
assessed by Western blot (right panel). One representative data set out of 3 to 5 independent experiments is shown for each 
panel.
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served viral element or it could associate with cellular pro-
teins that modulate viral infection specifically in DCs. To
distinguish between these possibilities, the effect of Vpx-
VLPs pre-incubation was evaluated on the infectivity of a
larger panel of retroviral vectors (HIV-1 as control, the
feline immunodeficiency virus, FIV, and the murine
leukemia gammaretrovirus, MLV). Cells were exposed to
Vpx-VLPs for 2 hours prior to infection with an equal
amount of infectious GFP-coding vectors and flow cytom-
etry analysis was carried out 3 days later (Fig. 3A). In the
absence of pre-incubation, HIV-1 LVs infected DCs at a
much higher rate than FIV LVs, while MLV vectors were
totally non-infectious. Vpx-VLPs pre-incubation of DCs
strongly increased both HIV-1 and FIV LVs infection effi-
ciencies (from 10 to 95% and from virtually undetectable
to 10%, respectively), while MLV remained non-infec-
tious, as previously shown [22].
To characterize the effect of Vpx on heterologous viruses
infection, the accumulation of viral DNA products was
examined (Fig. 3B, 3C and 3D). Vpx-VLPs pre-incubation
dramatically increased the levels of FL viral DNA at 24 hrs
following HIV-1, FIV and surprisingly also MLV infection,
despite the presence of similar levels of MSSS (Fig. 3B, 3C,
3D, from 10 to 30-fold depending on the virus). For HIV-
1 and FIV, the increase in 2LTR DNA was proportional to
the increase of FL DNA. In the case of MLV, the observed
increase in late RT products didn't result in the ability of
the virus to infect DCs. The absence of circular 2LTR
forms, indicative of viral DNA passage into the nucleus,
suggests that a major nuclear import block exists for MLV
in DCs that acts successively or dominantly over Vpx.
Overall, these results indicate that Vpx promotes the accu-
mulation of full length viral DNA in DCs following
Vpx allows the accumulation of full length viral DNA following SIVMAC infection of DCs Figure 2
Vpx allows the accumulation of full length viral DNA following SIVMAC infection of DCs. DCs were infected with 
normalized amounts of SIVMAC LVs containing or not Vpx (MOI of 2). Cell aliquots were harvested at 4 and 24 hrs post-infec-
tion and analyzed by semi-quantitative PCR (serial five-fold sample DNA dilutions) using primers that recognized specifically 
early (MSSS) and late (FL and 2LTRs) products of reverse transcription. The amount of sample added in the PCR reaction 
decreases from right to left, as represented by triangles: sample amount). Amplification of mitochondrial DNA (mtDNA) was 
used for normalization. PCR products were transferred onto a nylon membrane and hybridized with 32P-labelled specific 
probes prior to phosphor imager analysis and quantification. One representative data set out of 4 independent experiments is 
shown here.
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homologous as well as heterologous retrovirus infection.
Given the low sequence conservation between viral ele-
ments of MLV, FIV and HIV, we believe these results
strongly argue that Vpx modifies the intracellular environ-
ment of DCs to the virus advantage.
Vpx increases the kinetic of infectious viral DNA 
accumulation in DCs
Viral DNA accumulation most likely relies on multiple
factors such as RT synthesis rates and viral nucleoprotein
complexes stability or trafficking to favorable intracellular
locations. To gain further insights into Vpx function, a
more detailed time course analysis of complete reverse
transcripts accumulation was carried out on DCs infected
with HIV-1 LVs with or without Vpx-VLPs pre-incubation
(Fig. 4A). HIV-1 was chosen because Vpx had important
effects on its infectivity and because reverse transcription
could be blocked with Nevirapine, a potent reverse tran-
scriptase inhibitor (see below). In the absence of pre-incu-
bation, FL DNA accumulation proceeded rather slowly for
the first 7 hrs of infection and increased linearly thereafter
up to 48 hrs. On the contrary, in presence of Vpx-VLPs
pre-incubation HIV-1 FL viral DNA accumulated rapidly
within the first 7 hrs and increased only marginally there-
after. By 48 hrs post-infection the overall amounts of FL
viral DNA attained similar levels in both conditions
(within 2–3-fold as opposed to the 20-fold difference
observed at 7 hrs). However, despite the fact that similar
levels of FL viral DNA were reached at 48 hrs post-infec-
tion, HIV-1 infection rates were much higher upon Vpx-
VLPs pre-incubation (see for example Fig. 1C and 3A).
To prove that viral genomes synthesized early in presence
of Vpx are truly infectious and that they have an advantage
over DNA produced at later times, DCs were infected with
HIV-1 LVs (at MOI 1 and 10) in presence or absence of
Vpx-VLPs pre-incubation. Infections were blocked after 7
hrs with the nonnucleoside inhibitor Nevirapine and
compared to untreated samples 5 days post-infection by
flow cytometry (Fig. 4B). Nevirapine is a potent RT inhib-
itor and blocks efficiently viral infection. However, the
drug has no effect on the migration, integration and
expression of already completed viral DNA. Our analysis
indicates that contrarily to WT, the majority of viral
Vpx exerts a general positive effect on lentiviral infection and results in an increased accumulation of full length viral DNA Figure 3
Vpx exerts a general positive effect on lentiviral infection and results in an increased accumulation of full 
length viral DNA. A) Infections of DCs were carried out with VSVg-pseudotyped retroviral vectors bearing a CMV-GFP 
expression cassette (RVs, MOI 5) with or without Vpx-VLPs pre-incubation (MOI equivalent of 2, measured by exo-RT activity 
in comparison with standards of known infectivity). The percentage of infected cells was determined by flow cytometry 72 
hours afterwards. B) DCs were pre-incubated with Vpx-VLPs at an MOI equivalent of 2 for 2 hrs prior to infection with a con-
stant amount of HIV-1 (B), FIV (C) and MLV retroviral vectors (RV, D) at MOI 5. Cell aliquots were harvested at 4 and 24 hrs 
post-infection for HIV-1 and at 24 hrs only for FIV and MLV and analyzed by semi-quantitative PCR on serial five-fold sample 
dilutions (sample amount represented by triangles, as in the legend to Fig. 2), using primers that recognized specifically early 
and late products of reverse transcription. Amplification of actin DNA (actin) was used for normalization. For MLV, the posi-
tive control for 2LTRs amplification is represented by cell lysates of HeLa cells obtained 24 hrs post-infection with 10 fold less 
MLV vector than was used for DCs. PCR products were transferred onto a nylon membrane and hybridized with 32P-labelled 
specific probes prior to phosphor imager analysis and quantification. One representative data set out of 3 to 4 independent 
experiments is shown here.
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genomes has already been completed by 7 hrs post-infec-
tion. Indeed, the percentage of GFP+ cells is similar if the
drug is absent or added at this early time point.
Vpx-mediated accumulation of full length viral DNA 
occurs independently from arsenate
Arsenic acid is a drug known to enhance reverse transcrip-
tion efficiency in certain cell types by an unknown mech-
anism [23]. As Vpx enhances also viral DNA
accumulation, we sought to determine if Vpx and arsenate
acted along the same pathway. The possible effects of arse-
nate and of Vpx-VLPs pre-incubation of DCs were deter-
mined on SIVMAC LVs lacking Vpx or HIV-1 LVs (Fig. 5A
and 5B, respectively). Arsenic acid did not rescue the
infectivity defect of SIVMAC  LVs devoid of Vpx, but
increased the efficiency of infection to a mild extent when
Vpx was present. Arsenic acid increased as well HIV-1
infectivity independently of Vpx-VLPs pre-incubation. In
both cases, the effect of arsenic acid on viral infectivity was
negligible (from 1.5 to 3 fold increase) when compared to
the effect of Vpx. These results suggest that Vpx promotes
viral DNA accumulation via a separate mechanism.
Vpx counteracts a proteasome-dependent pathway in DCs
Since proteasome inhibitors have been shown to influ-
ence viral infectivity by modulating the accumulation and
stability of viral DNAs [24-28], we sought to determine if
Vpx could interfere with this pathway. The proteasome
inhibitors MG132, lactacystine and epoxomicin were ini-
tially tested, but only MG132 was retained due to its lower
toxicity. Even so, DCs remained viable only if MG132
treatment was limited to a very short time (7 hrs at 1 μg/
ml). To determine if MG132 could rescue the infectivity
defect of Vpx-deficient SIVMAC LVs, DCs were infected in
presence or absence of the drug for 7 hrs prior to media
replacement and drug and virus removal. If cells were ana-
lyzed by flow cytometry 2 days later, MG132 treatment
didn't consistently rescue the infectivity defect caused by
the absence of Vpx (data not shown). We hypothesized
this could be due to the drastic defect of Vpx-deficient SIV-
MAC LVs and to the short time of treatment to which the
Vpx allows faster rates of complete and infectious viral DNA accumulation following HIV-1 infection Figure 4
Vpx allows faster rates of complete and infectious viral DNA accumulation following HIV-1 infection. A) DCs 
were infected with a constant amount of HIV-1 LVs with or without Vpx-VLPs pre-incubation. Cell aliquots were harvested at 
times comprised between 4 and 48 hrs post-infection and the accumulation of FL viral DNA analyzed by semi-quantitative PCR. 
PCR products were quantified by phosphor imager (ordinate) after southern blot and hybridization analysis and input DNA 
normalization and are presented here in function of time (abscissa). B) DCs were infected with HIV-1 LVs with or without 
Vpx-VLPs pre-incubation and infection's rates obtained under normal conditions were compared with those obtained by inhib-
iting RT synthesis by addition of the nonnucleoside RT inhibitor Nevirapine at 7 hrs post-infection (10 μg/ml, this concentra-
tion inhibits completely viral infection if provided at the time of infection, not shown). GFP positive cells were analyzed by flow 
cytometry 5 days post infection. One representative data out of 2 independent experiments are presented for each panel.
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experiments were constrained. However, if infections
were analyzed by PCR 24 hrs post-infection, MG132 par-
tially relieved the block in FL viral DNA accumulation (by
12.5-fold, Fig. 5C). On the contrary, MG132 had only a
marginal effect on the amount of viral DNA accumulated
in presence of Vpx (1–2 fold). Thus, MG132 induced FL
DNA accumulation similarly but not additively to Vpx. It
may be possible that a more complete restoration of FL
DNA levels could have been obtained for LVs devoid of
Vpx with longer exposures or higher concentrations of
MG132 and that this could have yielded to a consequent
detection of GFP-positive cells by flow cytometry. How-
ever, the toxicity of the drug on DCs precluded these pos-
sibilities.
Given that the defect of Vpx-deficient SIVMAC LVs was
rather drastic, we hypothesized that the interplay between
MG132 and Vpx could be better revealed in more permis-
Vpx and the proteasome inhibitor MG132, but not Arsenate, display similar effects on the infection of DCs Figure 5
Vpx and the proteasome inhibitor MG132, but not Arsenate, display similar effects on the infection of DCs. A) 
DCs were either infected with Vpx-deficient SIVMAC or HIV-1 LVs (A and B, respectively, at MOI of 0.5 and 5) and treated sin-
gularly or in combination with 1 μM arsenic acid (As2O3) and Vpx-VLPs (at MOI equivalents of 0,5 and 2,5). The efficiency of 
infection was evaluated 72 hrs after by flow cytometry analysis. C) DCs were infected with Vpx containing or deficient SIVMAC 
LVs (MOI 5) in presence or absence of MG132 (1 μg/ml). The drug was added 30 min prior to infection then left for a total of 
7 hrs prior to cell washing and media replacement. DCs were then lysed at 24 hrs post-infection for FL PCR analysis as 
described in the legend of Fig. 5A. Results are presented as a fold increase in FL DNA for each condition with respect to the 
amount produced upon infection with Vpx-deficient SIVMAC LVs. D) DCs were similarly infected with a constant amount of 
HIV-1 LVs in presence or absence of MG132 and 2 different amounts of Vpx-VLPs. Media was replaced 7 hrs post-drug addi-
tion and cells analyzed 2 days afterwards by flow cytometry. One representative experiment out of 3 is shown here for each 
panel.
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sive conditions such as in the context of pre-incubation
assays (Fig. 5D). DCs were infected with a constant
amount of HIV-1 LVs and treated with MG132 in presence
or absence of Vpx-VLPs (at MOI equivalents of 0.05 and
0.5). In the absence of Vpx-VLPs pre-incubation, MG132
increased the infectivity of HIV-1 to levels achieved upon
VLPs pre-incubation (30-fold on average). As shown
above for SIVMAC, MG132 had only marginal effects on
HIV-1 infectivity when Vpx-VLPs were present, suggesting
that Vpx and MG132 act by similar mechanisms. These
results suggest that the function of Vpx in the infection of
DCs may be to counteract a proteasome-dependent
restriction.
Discussion
Our data support the notion that Vpx of the SIVSM/HIV-2
lineage allows the efficient accumulation of complete
viral DNA by counteracting a proteasome-dependent
restriction pathway specifically in DCs. We have not
observed a similar role of Vpx in the infection of other
non-dividing cell types such as macrophages or IL7-stim-
ulated PBLs, although Vpx had a minor stimulating effect
on the former cell type [20]. This suggests that the restric-
tion pathway that is targeted by Vpx is particularly active
in DCs with respect to other cell types.
We believe that multiple evidences support the hypothesis
that Vpx modifies DCs by counteracting a specific restric-
tion mechanism. Vpx provided in trans in target DCs
induces the accumulation of viral DNAs following infec-
tion with quite distantly related retroviruses, excluding
the possibility that Vpx acts on conserved viral elements.
This function of Vpx is specific to immature DCs (as well
as mature DCs, not shown). Lastly, the positive effect of
Vpx is maintained if Vpx-VLPs and infectious LVs enter
DCs via distinct entry pathways (RD114, GALV and VSVg,
not shown), supporting the notion that Vpx targets cellu-
lar rather than viral components.
The kinetic analysis of full length viral DNA accumulation
following HIV-1 infection revealed that Vpx speeds up the
completion of the RT process, a reaction that seems rela-
tively slow in DCs. Indeed, the majority of viral DNA is
synthesized by 7 hrs in presence of Vpx as opposed to 48
hrs in its absence. Despite the fact that at 48 hrs post-infec-
tion equivalent amounts of viral DNA accumulated in
both conditions, the viral DNA synthesized in presence of
Vpx is by far more infectious. This suggests that viral
genomes that are not completed in a short time are more
likely to be targeted by anti-viral cellular defense mecha-
nisms that diminish their infectivity. Given that the viral
DNA is contained within a nucleoprotein complex that
chaperones it through its life cycle, such defenses may act
at multiple steps. In this respect, by promoting the com-
pletion of viral DNA synthesis by RT, Vpx may drive struc-
tural rearrangements in viral complexes that alter their
stability or their trafficking within the cytoplasm with the
result of protecting them.
Several results shown here argue that the block relieved by
Vpx in DCs utilizes the proteasome. In fact, the proteas-
ome inhibitor MG132 partially rescued the accumulation
of full length viral DNA after infection with SIVMAC LVs
lacking Vpx. MG132 had an effect of the same order of
magnitude of Vpx on HIV-1 infection but the two effects
were not additive. Lastly, the positive effect of proteasome
inhibitors on viral infection of most cell types appears
much milder than the one observed here in DCs ([24-28]
between 3 to 7 fold, as opposed to 30 fold on average in
DCs). Due to their high antigen processing ability, the
possibility that DCs display high levels of proteasome
activity is not unlikely. Although this hypothesis remains
to be tested, it may explain why Vpx is required specifi-
cally in DCs.
An alternative explanation for the phenomenon observed
here is that Vpx does not target a restriction pathway but
simply increases the overall efficiency of RT synthesis by
altering the intracellular dNTP pool. Although such
hypothesis has not been tested directly, we believe it
unlikely because early RT products (MSSS) are unaffected
by Vpx.
A Vif-insensitive restriction block specified by APOBEC3G
molecules present in the form of low molecular weight
complexes has been described in cells resistant to HIV-1
infection, such as quiescent lymphocytes, monocytes and
more recently DCs [29,30]. However, Vpx doesn't restore
HIV-1 infection in quiescent lymphocytes nor monocytes
(not shown) making it unlikely, although formally possi-
ble, that Vpx acts by inhibiting APOBEC.
Our data may be reminiscent of the tripartite motif pro-
tein 5alpha-induced restriction (TRIM5α) and of its nega-
tive impact on lentiviral infection [31,32]. However, we
believe that the effect described here are independent
from TRIM5α-mediated restriction. Indeed, the defect of
Vpx-deficient SIVMAC LVs is not relieved with increasing
amounts of viral targets and human TRIM5α is not known
to target HIV-1 nor SIVMAC infection. This suggests that
Vpx may act by counteracting a distinct restriction path-
way that remains to be identified.
Conclusion
Vpx is required for viral spread and dissemination of
SIVSM in macaques. Our data indicates that Vpx exerts a
unique function in lentiviral infection of DCs by promot-
ing a rapid accumulation of complete viral DNA forms
and in mediating the escape of viral genomes from a pro-
teasome-dependent pathway that restricts viral infectionRetrovirology 2007, 4:2 http://www.retrovirology.com/content/4/1/2
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in such cells. Given the central role of DCs in viral spread,
these results may partly explain the drastic phenotype of
Vpx mutants in vivo.
Methods
Cells
Human primary lymphocytes and monocytes were
obtained from peripheral blood mononuclear cells
(PBMCs) of healthy donors at the Etablissement Français
du Sang de Lyon [33]. Monocytes obtained by negative
selection to more than 95% purity (MACS microbeads,
Miltenyi Biotec), were further differentiated in immature
dendritic cells (DCs) upon culture for 4–6 days in GM-
CSF/IL4 (100 ng/ml [34]). Human 293T were maintained
in complete DMEM plus 10% FCS. When indicated, arse-
nate was used at 1 μM and left on cells throughout the
experiment. MG132 (SIGMA) was used at 1 μg/ml for a
total of 7 hrs prior to media replacement and was added
30 min prior to infection.
Retroviral vectors
The HIV-1, SIVMAC251 (SIVMAC in the text), HIV-2 and FIV-
based lentiviral vectors, as well as the murine leukemia
virus (MLV) retroviral vector have been described else-
where [21,35-38]. They share similar conceptions and are
obtained upon transfection with: packaging constructs
coding gag-pro-pol and viral accessory proteins; a miniviral
genome bearing a CMV-GFP expression cassette; and a
vesicular stomatitis virus G envelope protein (VSVg) that
confers them ample cellular tropism [21,22,35,38,39].
Retroviral vectors and non infectious virion-like-particles
(lacking therefore a viral genome but otherwise identical
to infectious particles) were produced by calcium phos-
phate DNA transfection of 293T cells and purified by
ultracentrifugation through a double-step sucrose cushion
(45/25% w/v, as in ref [33]). Virions were normalized by
exogenous reverse transcriptase assay (exo-RT) with stand-
ards of known infectivity or by determining their infec-
tious titers on HeLa cells and no appreciable differences
were observed between the two methods. Infections were
carried out for 2 hrs prior to cell washing and cells exam-
ined 72 hours after by flow cytometry, unless otherwise
specified. Routine control infections were performed with
RT inhibitors to exclude pseudotransduction.
The SIVMAC Vpx-deficient packaging construct has been
described previously (SIV15-, [21]). The HIV-2 Vpx-defi-
cient packaging construct was derived from the initial
pSVRΔNB construct [39], by introducing a deletion
encompassing nucleotides 69–283 of vpx  by digestion
with the unique enzyme NsiI present within its sequence
and Bal31 nuclease digestion (HIV-2 Vpx-). Unless other-
wise specified, non-infectious SIVMAC Vpx containing VLPs
were produced from complete packaging vectors and
VSVg pseudotyped (Vpx-VLPs in the text), as we had
shown that Vpx is the only protein of SIVMAC required for
their positive effect [20]. In a typical pre-incubation assay,
Vpx-VLPs are added to target cells 2 hrs prior to infection
at MOI equivalents comprised between 1 and 2. HIV-1
Vpr and Vpx proteins were expressed from pHA-Vpr and
pTG651, respectively [10,20]. When indicated, Vpx pro-
teins were Flagged at their N-terminus.
Antibodies
Monoclonal antibodies were from the AIDS reagent and
reference program of the NIH (anti-SIV CA # 3537), and
Sigma (anti-Flag epitope, clone M2).
Analysis of reverse transcription intermediates
Infections were generally carried out at MOIs comprised
between 2 and 10 and PCR analysis carried out on serial
five-fold dilutions of cellular lysate, as previously
described [33]. Primer sequences were as follows (from 5'
to 3', nt within brackets refers to the complete SIVMAC251,
HIV-1, FIV or MLV sequences; acc. n°D01065, M38432,
NC_001482 and Z1118, respectively): minus-strand
strong-stop, MSSS, PE103-AGTCGCTCTGCGGAGAG-
GCTG (nt 507–527) and PE83-TGCTAGGGATTTTC-
CTGC (nt 789–807) for SIVMAC251, AC35-
GCCTCAATAAAGC TTGCCTTG (nt 522–542) and
AC117-GCATG CTGCTAGAGATTTTCCACAC (nt 616–
635) for HIV-1, AC373-GAGTCTCTTTGTTGAG
GACTTTTG (nt 217–240) and AC374-TGCG AAGT-
TCTCGGCCCGGATTCCG (nt 331–355) for FIV, AC311-
GTCCTCCGATAGACTGAGT C and AC312-GTAGTCAAT-
CACTCTGAG for MLV; full length, FL, 39-CCGTCGT-
GGTTGG TTCCTGCCG (nt 878–899) and 40-GCTAGA
TACCCAGAAGAGTTGGAAG (nt 294–309) for SIVMAC251,
AC37-CACTCCCAACGAAGAC AAG (nt 9100–9120) and
AC38-CAGCAAGCC GAGTCCTGCGT for HIV-1 (nt 699–
708), AC375-TGGGATGAGTATTGGAACCCTGAA G (nt
1–25) and AC376-TTTCTATTGCTCTAG CTTCACTTCC
(nt 394–419) for FIV, AC310-CTCAGCAGTTTCTTAA-
GACCC (nt 8094–8114) and AC267-GATCT-
GAGCCTATTGATC GATC (nt 44–65) for MLV; 2LTRs
circles, PE107-AGCTGCCATTTTAGAAGTAAGCC (nt
664–686) and PE151-TCTGACAGGCCTGA CTTGC (nt
318–336) for SIVMAC251, AC34-TCC CAGGCTCAGATCT-
GGTCTAAC (nt 465–489) and AC35 for HIV-1, AC377-
TGTCGAGTAT CTGTGTAATCTTTTTTACC (nt 292–320)
and AC378-AAAAGTCCTCAACAAAGAGACTC (nt 217–
239) for FIV, AC292-GCTGTTGCAT CCGACTCGTG (nt
60–79) and AC293-CACC GCAGATATCCTGTTTG (nt
7975–7994) for MLV ; mitochondrial DNA, 98-GAAT-
GTCTG CACAGCCACTTTCCAC and 99-GATCGTGG
TGATTTAGAGGGTGAAC; actinup-CGAGA AGATGAC-
CCAGATC, actindown-TGCCGCC AGACAGCACTGTG.
Probe sequences were: primer PE107 for SIVMAC251 MSSS
and FL; primer 40 for SIVMAC251 2LTRs; primer AC36-
TAGAGATCCCTCAGACCCTT (nt 589–608) for HIV-1Retrovirology 2007, 4:2 http://www.retrovirology.com/content/4/1/2
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MSSS, FL and 2LTRs; primer AC292 for MLV MSSS and FL,
AC 312 for MLV 2LTRs; mitoprobe100-TGGGGTTTGGC
AGAGATGT; actinprobe-GGAGAAGAGCTA CGAGCTGC.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CG: carried out experiments, data analysis and contrib-
uted to writing of the manuscript
LR: carried out initial cloning of Vpx proteins from differ-
ent SIV strains
LJW: purified blood material, tested proteasome inhibi-
tors cytotoxicity and contributed to virion preparations
JB: provided blood material
DR: provided blood material
JLD: data analysis and study design
AC: study design, data interpretation and supervision
Acknowledgements
We are indebted to the AIDS reagents and reference program of the NIH; 
to Eric Poeschla, Andrew Lever, Arya Suresh, Jeremy Luban and François-
Loic Cosset for the kind sharing of reagents. We thank Pascal Leblanc for 
critical reading of the manuscript. AC is funded by Sidaction, ANRS and the 
NIH; JLD and CG by the TRIoH consortium of the EC.
References
1. Tristem M, Marshall C, Karpas A, Hill F: Evolution of the primate
lentiviruses: evidence from vpx and vpr.  Embo J 1992,
11:3405-3412.
2. Hirsch VM, Sharkey ME, Brown CR, Brichacek B, Goldstein S, Wake-
field J, Byrum R, Elkins WR, Hahn BH, Lifson JD, Stevenson M: Vpx
is required for dissemination and pathogenesis of SIV(SM)
PBj: evidence of macrophage-dependent viral amplification.
Nat Med 1998, 4:1401-1408.
3. Mueller SM, Jung R, Weiler S, Lang SM: Vpx proteins of
SIVmac239 and HIV-2ROD interact with the cytoskeletal
protein alpha-actinin 1.  J Gen Virol 2004, 85:3291-3303.
4. Mahalingam S, Van Tine B, Santiago ML, Gao F, Shaw GM, Hahn BH:
Functional analysis of the simian immunodeficiency virus
Vpx protein: identification of packaging determinants and a
novel nuclear targeting domain.  J Virol 2001, 75:362-374.
5. Fletcher TM 3rd, Brichacek B, Sharova N, Newman MA, Stivahtis G,
Sharp PM, Emerman M, Hahn BH, Stevenson M: Nuclear import
and cell cycle arrest functions of the HIV-1 Vpr protein are
encoded by two separate genes in HIV-2/SIV(SM).  Embo J
1996, 15:6155-6165.
6. Pancio HA, Vander Heyden N, Ratner L: The C-terminal proline-
rich tail of human immunodeficiency virus type 2 Vpx is nec-
essary for nuclear localization of the viral preintegration
complex in nondividing cells.  J Virol 2000, 74:6162-6167.
7. Belshan M, Ratner L: Identification of the nuclear localization
signal of human immunodeficiency virus type 2 Vpx.  Virology
2003, 311:7-15.
8. Rajendra Kumar P, Singhal PK, Vinod SS, Mahalingam S: A non-
canonical transferable signal mediates nuclear import of
simian immunodeficiency virus Vpx protein.  J Mol Biol 2003,
331:1141-1156.
9. Belshan M, Mahnke LA, Ratner L: Conserved amino acids of the
human immunodeficiency virus type 2 Vpx nuclear localiza-
tion signal are critical for nuclear targeting of the viral pre-
integration complex in non-dividing cells.  Virology 2006,
346:118-126.
10. Re F, Braaten D, Franke EK, Luban J: Human immunodeficiency
virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the
activation of p34cdc2-cyclin B.  J Virol 1995, 69:6859-6864.
11. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR: Muta-
tional analysis of cell cycle arrest, nuclear localization and
virion packaging of human immunodeficiency virus type 1
Vpr.  J Virol 1995, 69:7909-7916.
12. Poon B, Grovit-Ferbas K, Stewart SA, Chen IS: Cell cycle arrest by
Vpr in HIV-1 virions and insensitivity to antiretroviral
agents.  Science 1998, 281:266-269.
13. Park IW, Sodroski J: Functional analysis of the vpx, vpr, and nef
genes of simian immunodeficiency virus.  J Acquir Immune Defic
Syndr Hum Retrovirol 1995, 8:335-344.
14. Akari H, Sakuragi J, Takebe Y, Tomonaga K, Kawamura M, Fukasawa
M, Miura T, Shinjo T, Hayami M: Biological characterization of
human immunodeficiency virus type 1 and type 2 mutants in
human peripheral blood mononuclear cells.  Arch Virol 1992,
123:157-167.
15. Yu XF, Yu QC, Essex M, Lee TH: The vpx gene of simian immu-
nodeficiency virus facilitates efficient viral replication in
fresh lymphocytes and macrophage.  J Virol 1991, 65:5088-5091.
16. Guyader M, Emerman M, Montagnier L, Peden K: VPX mutants of
HIV-2 are infectious in established cell lines but display a
severe defect in peripheral blood lymphocytes.  Embo J 1989,
8:1169-1175.
17. Kawamura M, Sakai H, Adachi A: Human immunodeficiency
virus Vpx is required for the early phase of replication in
peripheral blood mononuclear cells.  Microbiol Immunol 1994,
38:871-878.
18. Kappes JC, Conway JA, Lee SW, Shaw GM, Hahn BH: Human
immunodeficiency virus type 2 vpx protein augments viral
infectivity.  Virology 1991, 184:197-209.
19. Ueno F, Shiota H, Miyaura M, Yoshida A, Sakurai A, Tatsuki J, Koyama
AH, Akari H, Adachi A, Fujita M: Vpx and Vpr proteins of HIV-2
up-regulate the viral infectivity by a distinct mechanism in
lymphocytic cells.  Microbes Infect 2003, 5:387-395.
20. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cima-
relli A: With a little help from a friend: increasing HIV trans-
duction of monocyte-derived dendritic cells with virion-like
particles of SIV(MAC).  Gene Ther 2006, 13:991-994.
21. Mangeot PE, Duperrier K, Negre D, Boson B, Rigal D, Cosset FL, Dar-
lix JL: High levels of transduction of human dendritic cells
with optimized SIV vectors.  Mol Ther 2002, 5:283-290.
22. Jarrosson-Wuilleme L, Goujon C, Bernaud J, Rigal D, Darlix JL, Cima-
relli A: Transduction of nondividing human macrophages
with gammaretrovirus-derived vectors.  J Virol 2006,
80:1152-1159.
23. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J:
As(2)O(3) Enhances Retroviral Reverse Transcription and
Counteracts Ref1 Antiviral Activity.  J Virol 2003, 77:3167-3180.
24. Butler SL, Johnson EP, Bushman FD: Human immunodeficiency
virus cDNA metabolism: notable stability of two-long termi-
nal repeat circles.  J Virol 2002, 76:3739-3747.
25. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ: Proteas-
ome inhibitors uncouple rhesus TRIM5alpha restriction of
HIV-1 reverse transcription and infection.  Proc Natl Acad Sci
USA 2006, 103:7465-7470.
26. Santoni de Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L: Pro-
teasome activity restricts lentiviral gene transfer into
hematopoietic stem cells and is down-regulated by cytokines
that enhance transduction.  Blood 2006, 107:4257-4265.
27. Wei BL, Denton PW, O'Neill E, Luo T, Foster JL, Garcia JV: Inhibi-
tion of lysosome and proteasome function enhances human
immunodeficiency virus type 1 infection.  J Virol 2005,
79:5705-5712.
28. Schwartz O, Marechal V, Friguet B, Arenzana-Seisdedos F, Heard JM:
Antiviral activity of the proteasome on incoming human
immunodeficiency virus type 1.  J Virol 1998, 72:3845-3850.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2007, 4:2 http://www.retrovirology.com/content/4/1/2
Page 11 of 11
(page number not for citation purposes)
29. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene
WC: Cellular APOBEC3G restricts HIV-1 infection in resting
CD4+ T cells.  Nature 2005, 435:108-114.
30. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman
RM, Piguet V: APOBEC3G/3F mediates intrinsic resistance of
monocyte-derived dendritic cells to HIV-1 infection.  J Exp
Med 2006. [ePub Dec4]
31. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski
J: The cytoplasmic body component TRIM5alpha restricts
HIV-1 infection in Old World monkeys.  Nature 2004,
427:848-853.
32. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ: Differ-
ential restriction of human immunodeficiency virus type 2
and simian immunodeficiency virus SIVmac by TRIM5alpha
alleles.  J Virol 2005, 79:11580-11587.
33. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cima-
relli A: Heterologous human immunodeficiency virus type 1
lentiviral vectors packaging a simian immunodeficiency
virus-derived genome display a specific postentry transduc-
tion defect in dendritic cells.  J Virol 2003, 77:9295-9304.
34. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Nieder-
wieser D, Schuler G: Generation of mature dendritic cells from
human blood. An improved method with special regard to
clinical applicability.  J Immunol Methods 1996, 196:137-151.
35. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM,
Trono D: In vivo gene delivery and stable transduction of non-
dividing cells by a lentiviral vector.  Science 1996, 272:263-267.
36. D'Costa J, Brown H, Kundra P, Davis-Warren A, Arya S: Human
immunodeficiency virus type 2 lentiviral vectors: packaging
signal and splice donor in expression and encapsidation.  J Gen
Virol 2001, 82:425-434.
37. Strappe PM, Hampton DW, Brown D, Cachon-Gonzalez B, Caldwell
M, Fawcett JW, Lever AM: Identification of unique reciprocal
and non reciprocal cross packaging relationships between
HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral
vector system with highly favourable features for in vivo test-
ing and clinical usage.  Retrovirology 2005, 2:55.
38. Saenz DT, Teo W, Olsen JC, Poeschla EM: Restriction of feline
immunodeficiency virus by Ref1, Lv1, and primate
TRIM5alpha proteins.  J Virol 2005, 79:15175-15188.
39. Griffin SD, Allen JF, Lever AM: The major human immunodefi-
ciency virus type 2 (HIV-2) packaging signal is present on all
HIV-2 RNA species: cotranslational RNA encapsidation and
limitation of Gag protein confer specificity.  J Virol 2001,
75:12058-12069.
40. Kewalramani VN, Emerman M: Vpx association with mature
core structures of HIV-2.  Virology 1996, 218:159-168.